Company: PTPI
Filing Date: 2025-03-18
Form Type: DEF 14A
Source: 0001104659-25-025104
Chunk: 28

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-18
Form: DEF 14A
Chunk 28
---
arrant to us together with the appropriate instruments
of transfer.

Fractional Shares

No fractional shares of Common Stock will be issued upon the exercise
of the Series A Warrants. Rather, the number of shares of Common Stock to be issued will, at our election, either be rounded up to
the next whole share or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the exercise price.

<div align='center'>17</div>

Trading Market

There is no established trading market for the
Series A Warrants, and we do not expect an active trading market to develop. We do not intend to apply to list the Series A
Warrants on any securities exchange or other trading market. Without a trading market, the liquidity of the Series A Warrants will
be extremely limited.

Right as a Stockholder

Except as otherwise provided in the Series A Warrants or by virtue
of such holder’s ownership of our shares of Common Stock, the holder of a Series A Warrant does not have the rights or privileges
of a holder of our Common Stock, including any voting rights, until the holder exercises the Series A Warrant.

Waivers and Amendments

The Series A Warrants may be modified or
amended, or the provisions thereof waived with the written consent of the Company and the respective holder.

Series B Warrants

The following summary of certain terms and provisions of the Series B Warrants is not complete and is subject to, and qualified in its entirety by, the provisions of the Series A Warrant, the form of which was filed as an exhibit to the Current Report on Form 8-K filed by the Company on February 21, 2025. Our security holders entitled to vote on the Issuance Proposal should carefully review the terms and provisions of the form of Series B Warrant for a complete description of the terms and conditions of the Series B Warrants.

Duration and Exercise Price

Each Series B Warrant is exercisable for one share of Common Stock,
has an exercise price equal to $0.48 per share, will become exercisable on the Initial Exercise Date and will expire on the one (1) year
anniversary of the Initial Exercise Date. The exercise price and number of shares of Common Stock issuable upon exercise of the Series B
Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting
our Common Stock and the exercise price. The Series B Warrants were